Continuous at-home monitoring with smart device-based photoplethysmography technology could be a viable strategy for AFib screening and early detection, according to a population-level study out of China.

French medtech startup Robocath has raised 5 million euros—the equivalent of $5.5 million in U.S. currency—in support of its cardiovascular robotics system, the company announced this month.

Men who live on their own—but not women—struggle to take warfarin as directed, according to research presented Sept. 2 at the ESC Congress in Paris.

The level of pragmatism in CV-related randomized clinical trials has only increased moderately over the past two decades, according to work published in JAMA Cardiology Sept. 1.

Three-year results from the BIO-RESORT trial revealed that despite significant differences in stent backbone and polymer coating, the ultrathin sirolimus-eluting stent, very-thin everolimus-eluting stent and thin-strut zotarolimus-eluting stent remained equally safe and effective through follow-up.

Researchers have uncovered evidence of a global “epidemiological transition” that’s seeing cancer overtake cardiovascular disease as the biggest killer in developed countries, Reuters reports.

Research presented this month at the ESC Congress in Paris suggests that getting a yearly influenza shot could greatly cut hypertensive patients’ risk of dying during flu season.

Complete revascularization is superior to culprit-lesion-only PCI in patients with both STEMI and multivessel disease, according to results from the COMPLETE trial, published Sept. 1 in the New England Journal of Medicine.

The U.S. FDA this month granted Fast Track designation to AstraZeneca for the development of Farxiga, or dapagliflozin. 

Cardiology compensation jumped 4.4% while productivity remained relatively stagnant between 2017 and 2018, AMGA reported in its 32nd annual Medical Group Compensation and Productivity Survey.